Aurinia Pharmaceuticals Inc. Share-based Payment Arrangement, Expense in USD from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aurinia Pharmaceuticals Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to Q3 2025.
  • Aurinia Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $5.92M, a 28.9% decline year-over-year.
  • Aurinia Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2024 was $31.6M, a 30.3% decline from 2023.
  • Aurinia Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $45.3M, a 40.3% increase from 2022.
  • Aurinia Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $32.3M, a 3.38% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

Aurinia Pharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $5.92M -$2.41M -28.9% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q1 2025 $28.5M $5.44M -$3.15M -36.6% Jan 1, 2025 Mar 31, 2025 10-Q 2025-07-31
Q4 2024 $31.6M $6.1M -$5.67M -48.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 $37.3M $8.33M -$3.48M -29.5% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 $40.7M $8.59M -$3.68M -30% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $44.4M $8.59M -$881K -9.31% Jan 1, 2024 Mar 31, 2024 10-Q 2025-07-31
Q4 2023 $45.3M $11.8M +$4.87M +70.5% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 $40.4M $11.8M +$3.49M +41.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $37M $12.3M +$2.21M +22% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 $34.7M $9.47M +$2.44M +34.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $32.3M $6.9M -$1.68M -19.5% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-27
Q3 2022 $34M $8.32M +$1.23M +17.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $32.7M $10.1M +$2.3M +29.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $30.4M $7.02M -$798K -10.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $31.2M $8.58M +$3.43M +66.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $27.8M $7.09M +$2.48M +53.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $25.3M $7.75M +$3.55M +84.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $21.8M $7.82M +$4.33M +124% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $17.5M $5.15M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $4.61M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $4.2M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $3.5M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06

Aurinia Pharmaceuticals Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $31.6M -$13.7M -30.3% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $45.3M +$13M +40.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $32.3M +$1.06M +3.38% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 $31.2M +$13.8M +79% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 $17.5M +$10M +135% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $7.41M +$554K +8.08% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $6.86M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.